Drugs / SCB-1019T
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06666179 | Oct 2025 → Jun 2026 | respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
| Phase 1 | NCT06843317 | Mar 2025 → Mar 2026 overdue | respiratory syncytial virus infectious disease | Clover Biopharmaceuticals USA, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06194318 | Dec 2023 → Feb 2025 | respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06984094 Comparator | Jun 2025 → Mar 2028 expected | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-1019T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194318 ↗ |
| Modality | Vaccine | “The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain.” NCT06194318 ↗ |